Scholarlink

<p>Acute myocardial infarction (AMI) is one of the most important components of cardiovascular disorders and the leading cause of worldwide morbidity and mortality. High-sensitivity C-reactive protein (hs-CRP) is a significant inflammatory predictor of AMI. This investigation aimed to assess the effects of the leukotriene receptor antagonist Montelukast on hs-CRP amounts in the context of patients suffering from non-ST-elevation myocardial infarction (NSTEMI). We selected 64 patients with NSTEMI for this double-blind, randomized controlled trial. Primary laboratory tests, including hs-CRP, CBC diff, lipid profile, and interleukin-6 (IL-6), were performed at baseline. The treatment group received 10 mg of Montelukast twice daily, and the placebo group received tablets similar in size and shape to Montelukast, taken twice daily, in addition to their usual protocol. Lipid profile, CBC diff, IL-6, and hs-CRP were reassessed after a 4-week course of treatment. Our findings emphasized that hs-CRP and IL-6 values were notably diminished in NSTEMI patients in both the Montelukast and placebo groups, related to baseline (<i>P</i> &lt; 0.001). Interestingly, Montelukast robustly alleviated the hs-CRP and IL-6 amounts more than the placebo group following the 30-day treatment (<i>P</i> = 0.004 for both). A comparison between the two groups revealed that the mean changes in hs-CRP prior to and after treatment were statistically greater in the Montelukast group than in the placebo group (<i>P</i> = 0.002). The findings highlighted that Montelukast may mitigate inflammatory indicators, namely, hs-CRP and IL-6, and could be considered for NSTEMI patients. Otherwise, more clinical trials are required to determine its effectiveness in clinical administration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial

  • 期刊论文

  • 发表日期：

    2026年3月23日

查看全文
  • Bahram Shahri,
  • Vahid Reza Askari,
  • Soroush Fotouhi,
  • Asal Yadollahi,
  • Lida Jarahi,
  • Yaser Bakhoda,
  • Vafa Baradaran Rahimi

摘要

Acute myocardial infarction (AMI) is one of the most important components of cardiovascular disorders and the leading cause of worldwide morbidity and mortality. High-sensitivity C-reactive protein (hs-CRP) is a significant inflammatory predictor of AMI. This investigation aimed to assess the effects of the leukotriene receptor antagonist Montelukast on hs-CRP amounts in the context of patients suffering from non-ST-elevation myocardial infarction (NSTEMI). We selected 64 patients with NSTEMI for this double-blind, randomized controlled trial. Primary laboratory tests, including hs-CRP, CBC diff, lipid profile, and interleukin-6 (IL-6), were performed at baseline. The treatment group received 10 mg of Montelukast twice daily, and the placebo group received tablets similar in size and shape to Montelukast, taken twice daily, in addition to their usual protocol. Lipid profile, CBC diff, IL-6, and hs-CRP were reassessed after a 4-week course of treatment. Our findings emphasized that hs-CRP and IL-6 values were notably diminished in NSTEMI patients in both the Montelukast and placebo groups, related to baseline (P < 0.001). Interestingly, Montelukast robustly alleviated the hs-CRP and IL-6 amounts more than the placebo group following the 30-day treatment (P = 0.004 for both). A comparison between the two groups revealed that the mean changes in hs-CRP prior to and after treatment were statistically greater in the Montelukast group than in the placebo group (P = 0.002). The findings highlighted that Montelukast may mitigate inflammatory indicators, namely, hs-CRP and IL-6, and could be considered for NSTEMI patients. Otherwise, more clinical trials are required to determine its effectiveness in clinical administration.